

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 August 2023 (03.08.2023)



(10) International Publication Number
WO 2023/143583 A1

(51) International Patent Classification:

C07K 16/18 (2006.01) *C12N 5/16* (2006.01)
C12P 21/08 (2006.01) *A61P 7/00* (2006.01)
A61K 39/395 (2006.01)

NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/CN2023/073730

(22) International Filing Date:

29 January 2023 (29.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2022/074995

29 January 2022 (29.01.2022) CN

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicants: **KIRA PHARMACEUTICALS (SUZHOU) LTD.** [CN/CN]; 507 A4 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu 215000 (CN). **THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA** [US/US]; 3600 Civic Center Boulevard, 9th Floor, Philadelphia, PA 19104 (US).

(72) Inventors: **TSUI, Ping**; 15801 Chagall Terrace North Potomac, Maryland 20878 (US). **JIANG, Bingbing**; 507, A4 Building, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu 215000 (CN). **ZHANG, Jianjun**; 507, A4 Building, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu 215000 (CN). **XU, Yingying**; 507, A4 Building, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu 215000 (CN). **HU, Xiaoxia**; 507, A4 Building, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu 215000 (CN). **FEI, Dongqiong**; 507, A4 Building, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu 215000 (CN). **SONG, Wenchao**; 213 Cornell Drive, Bryn Mawr, PA 19010 (US). **MIWA, Takashi**; 191 Presidential Blvd., Unit 323, Bala Cynwyd, PA 19004 (US). **GULLIPALLI, Damodar**; 8403 Normandy Dr., Mount Laurel, NJ 08054 (US). **SATO, Sayaka**; 2130 Locust Street, Apt. # A1, Philadelphia, PA 19103 (US).

(74) Agent: **KANGXIN PARTNERS, P.C.**; Floor 16, Tower A, InDo Building, A48 Zhichun Road, Haidian District, Beijing 100098 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,

(54) Title: ANTI-C2 ANTIBODIES AND USES THEREOF

(57) Abstract: Provided is inhibition of the complement signaling using an anti-C2 antibody or a fragment thereof. Specifically, provided are methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with the anti-C2 antibody or a fragment thereof.

WO 2023/143583 A1